ZHZahraa Amer Hashim

Zahraa Amer Hashim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zahraa Amer Hashim has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Encountering the potentials of probiotics against urogenital tract infections in females

    by Zainab Abdullah Khaleel, Zahraa Amer Hashim, Vildan Celiksoy

    Urinary tract infection (UTI) and vaginitis are common conditions among females, significantly impacting overall life health and quality, imposing economical burdens and rising concerns of antibiotic resistance and limiting current treatments, probiotics have emerged as promising non antibiotic adjuvant and alternatives. Lactobacillus species restore and sustain a balanced microbiome offering protection against uro-pathogens by enhancement of epithelium barrier, immune modulation, competitive exclusions and biofilm disruptions. Clinical trials have documented the efficacy of probiotics both orally and vaginally in reducing UTI, preventing recurrences and restoring vaginal microbiota. This review highlights the aspects of probiotics mechanism of action, clinical trials and applications, exploring potentials of next generation probiotics and advancement in in delivery systems. While probiotics offer promising efficacy in managing UTI and vaginitis, further research studies are required to clarify exact mechanisms, strains potentials, dosage forms and doses, framing regulations regarding probiotics industry and tailored probiotics field.


  • Pharmaceutical products microbial contamination; approaches of detection and avoidance

    by Zahraa Amer Hashim, Vildan Celiksoy

    Pharmaceutical products’ microbial contamination is a serious worry in the pharmaceutical industry, as it can posture momentous health jeopardies to patients. Contamination with microbes can befall at any stage of manufacturing, starting with raw materials and ending with the finished products. It can also result from a variety of sources counting the environment, working personnel and equipment used. Common microorganisms that contaminate pharmaceutical products include bacteria, fungi, and viruses. The presence of these contaminants can compromise the quality, safety, and efficacy of pharmaceutical products, leading to product recalls, loss of reputation, and financial losses. Therefore, it is essential for pharmaceutical manufacturers to implement robust quality control measures to detect and prevent microbial contamination, including stringent cleaning and sanitation procedures, environmental monitoring, and microbiological testing. In this review, we discussed the main conventional and advanced technologies of detecting microbial contamination in pharmaceutical products. These techniques range from conventional culture methods to the more sophisticated technologies of gene sequencing and spectroscopy.


  • Open Access

    TAS2R38 gene in relation to Helicobacter pylori infection and blood groups in different age groups

    by Karam A. Aldabbagh, Zahraa Amer Hashim, Zahraa Sedeeq Qasim

    Of the factors predisposing to gastric cancer is Helicobacter pylori infection affecting more than 50% of the general population. Genetic variation is an established player in certain diseases susceptibility. TAS2R38 gene polymorphisms have been found to influence bitter taste ability to chemicals with malicious characteristics and consequently affect metabolism and disease development. This study aimed to investigate the correlation between TAS2R38 gene polymorphisms and H. pylori seropositivity. The study involved 105 apparently healthy individuals. They were grouped into four groups according to their age and gender; young male, young female, middle-aged male and middle-aged female. All groups were tested for H. pylori serum antibody using screening rapid test. Participants were also tested for tasting PTC for TAS2R38 gene detection by using Bartovation PTC test paper and grouped accordingly into: homozygote (highly bitter taste), heterozygote (slight to moderate bitter taste), or negative gene carrier (no taste at all). ABO and Rhesus- blood grouping was determined by standard serological analysis. Of the 105 patients, 22.85% were tested homozygotes for TAS2R38 gene, 40.95% were heterozygotes and 36.19% were nontasters, no significant difference (p > 0.9). H. pylori seropositivity was encountered in 16.19% of the whole participants, 11.5% of the male participants and 20.75% of the female participants (p > 0.9). No significant difference in seropositivity was monitored among the four age groups (p > 0.3) and the ABO/Rh blood groups (p > 0.9). A lack of significant correlation (r = 0.046) between H. pylori antibody test positivity and tasting PTC (TAS2R38 gene) was reported. Similarly, no association was found between PTC tasting and participants’ ABO blood grouping, age or gender (r = 0.086, 0.083 and 0.029, respectively). Yet, weak negative (reverse) relationship (r = -0.29, p-value = 0.002) was gained between PTC and Rh grouping. No correlation was revealed between TAS2R38 polymorphism and the studied variable; age, gender and blood group indicating the absence of an apparent role of the gene in vulnerability to H. pylori infection. Further studies involving a larger sample size is required to confirm the obtained result.


  • Open Access

    BACTERIOTHERAPY

    by Zahraa Amer Hashim

    The vaccination in Albania : An assessment of the level of knowledge and behaviour of the population regarding vaccines.

  • Open Access

    In vitro Assessment of the Antimicrobial Potential of Some Commercial Herbal Products

    by Zahraa A. Hashim

    Natural plant products have been widely used as an alternative approach to treat microbial infections to overcome issues of antibiotics-associated side effects and the emergence of resistant pathogens. One of the most popular infections causing significant morbidity and death toll is urinary tract infection. This study is designed to evaluate the antimicrobial and antibiofilm potential of four commercial herbal products against five uropathogenic clinical isolates. In vitro, well diffusion assay and crystal violet staining techniques were used to evaluate the antimicrobial and antibiofilm effects respectively. Antimicrobial effect was reported for Renalka™ against Enterococcus faecium, ROWAtinex® against Staphylococcus aureus and E. faecium and UROCLEAR against Candida albicans. A significant antibiofilm effect, semi-quantified by stained biomass, was reported for all of the products included in the study against the tested pathogens but to a varying degree. Medicinal herbal products can exert a substantial prophylactic antibiofilm effect in addition to their beneficial health effects in treating urological pathologies.

  • Open Access

    Determining the potential use of biosurfactants in preventing endodontic infections

    by Zahraa Amer Hashim, Jean‐Yves Maillard, Melanie Jay Wilson, Rachel Jane Waddington

    Microbial biofilms play a dominant role in the failure of endodontic therapies. Bacterial adhesion is the first step in the establishment of biofilms, activating the host immune response leading to tissue damage. Biosurfactants are microbe‐derived tensioactive molecules with latent anti‐adhesive and anti‐microbial activity. This study reports the extraction and characterization of a biosurfactant from Lactobacillus (L.) plantarum (Lp‐BS) and investigates its anti‐microbial and anti‐adhesive properties compared to rhamnolipid, a commercially available biosurfactant. Lp‐BS, extracted from L. plantarum during the growth phase, was characterized as a glycoprotein, able to reduce surface tension and emulsify non‐polar liquids. Proteomic analysis of Lp‐BS identified three bacterial adhesin‐like proteins, suggesting roles in hindering bacterial adhesion. Lp‐BS did not show significant anti‐microbial activity against endodontic pathogens from the Streptococcus (Strep.) anginosus group or Enterococcus (Ent.) faecalis at 50 mg/ml. However, anti‐adhesive activity on abiotic surfaces was observed against both Strep. anginosus and Strep. intermedius. Rhamnolipid exhibited strong anti‐microbial activity, with minimum inhibitory concentrations of 0.097 mg/ml against Strep. anginosus, and 0.048 mg/ml against Strep. constellatus and Strep. intermedius, in addition to a marked anti‐adhesive activity. These findings offer preliminary evidence for the potential application of biosurfactants as an anti‐microbial and/or anti‐adhesive pharmacotherapy in endodontics.


  • Open Access

    Bacteriophage as a Promising Alternative or Complementary Therapy to Antibiotics

    by Zahraa A. Hashim, Farah H. Omer

    The global issue of antibiotic resistance and the narrowing down of new antibiotic discoveries besides their cost has led to the reintroduction of bacteriophage as a focus of research projects. Phage therapy is mainly grounded on the discriminating ability of the bacteriophage to destroy the targeted bacterial cells, but not human cells, via lytic phages. Although there has been a number of life-sparing clinical trials and applications, this therapy is still facing challenging issues. This review gives an overview of the microbiology and history of the bacteriophages. It also reviews the past and current studies of phage therapy in humans and it’s commercial production. The aim of this study is to shed the light on the rapidly growing field of phage therapy and the obstacles that appear ahead as antimicrobial science moves away from broad dependence on conventional antibiotics.